Clin2
NCT07598708Likely a fitRecruiting

Cleminorexton for Narcolepsy: A New Treatment Study

Narcolepsy Type 1Narcolepsy Type 2

Part of Brain & nervous system, Mental health clinical trials.

This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
222 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old
  • Your BMI (weight-to-height ratio) is between 17 and 45 kg/m²
  • You have been diagnosed with Narcolepsy Type 1 or Type 2 by a sleep specialist
  • You are willing to stop taking all your current narcolepsy medications during the trial
  • You can follow the study schedule and requirements, including visits and possibly sleep monitoring

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06952699Recruiting· Phase 2
TAK-360 for narcolepsy type 2

This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.

Auburn, Alabama
NCT07540897Recruiting· Phase 3
Testing ALKS 2680 for narcolepsy type 1

This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.

Miami, Florida
NCT07455383Recruiting· Phase 3
Testing ALKS 2680 for adults with narcolepsy type 1

This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.

Cullman, Alabama
NCT07502443Recruiting· Phase 3
Study of ALKS 2680 for narcolepsy type 2

This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.

Cullman, Alabama
NCT07633301Recruiting· Phase 2
TAK-360 Study for Adults With Narcolepsy Type 1

This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.

Redwood City, California
NCT06752668Recruiting· Phase 2
Testing ORX750 for narcolepsy and idiopathic hypersomnia

This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.

Auburn, Alabama

Hear when a new Narcolepsy Type 1 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.